Literature DB >> 18936893

Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection.

Eiichi Ogawa1, Shigeru Otaguro, Masayuki Murata, Mosaburo Kainuma, Yasunori Sawayama, Norihiro Furusyo, Jun Hayashi.   

Abstract

Symptoms caused by acute human parvovirus B19 (HPV-B19) infection can vary considerably, from asymptomatic to severely symptomatic. A 39-year-old Japanese woman complained of sudden, severe arthralgia with edematous limbs coincident with an outbreak of HPV-B19 infection at the elementary school attended by her daughter. A diagnosis of acute HPV-B19 infection was made by the detection of serum antibody to HPV-B19 IgM and HPV-B19 DNA. Magnetic resonance imaging revealed bilateral synovitis of the cubital joints. The patient was immunocompetent and suffered from severe arthralgia associated with persistent HPV-B19 viremia for more than 4 months after the diagnosis of acute HPV-B19 infection. The administration of high-dose intravenous immunoglobulin resulted in remission, with little change in the serum HPV-B19 DNA level. Even in our immunocompetent patient, severe and prolonged arthritis was found to be associated with persistent viremia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18936893     DOI: 10.1007/s10156-008-0636-x

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  9 in total

Review 1.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

2.  Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India.

Authors:  Surjit Singh; Shanmuganathan Chandrakasan; Jasmina Ahluwalia; Deepti Suri; Amit Rawat; Nishath Ahmed; Reena Das; M U S Sachdeva; Neelam Varma
Journal:  Rheumatol Int       Date:  2011-01-11       Impact factor: 3.580

Review 3.  Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19.

Authors:  Xi Hu; Chen Jia; Jianyong Wu; Jian Zhang; Zhijie Jiang; Kuifen Ma
Journal:  Front Cell Infect Microbiol       Date:  2022-06-20       Impact factor: 6.073

4.  High-Throughput Screening Identifies Inhibitors for Parvovirus B19 Infection of Human Erythroid Progenitors.

Authors:  Kang Ning; Anuradha Roy; Fang Cheng; Peng Xu; Steve Kleiboeker; Carlos R Escalante; Jingxin Wang; Jianming Qiu
Journal:  J Virol       Date:  2021-10-20       Impact factor: 6.549

Review 5.  Viral arthritis.

Authors:  Michael Marks; Jonathan L Marks
Journal:  Clin Med (Lond)       Date:  2016-04       Impact factor: 2.659

6.  Persistent parvovirus B19 viremia with chronic arthralgia treated with ascorbic acid: a case report.

Authors:  Aloys Lallement; Christine Zandotti; Philippe Brouqui
Journal:  J Med Case Rep       Date:  2015-01-05

7.  Extra-haematological manifestations related to human parvovirus B19 infection: retrospective study in 25 adults.

Authors:  Marion Dollat; Benjamin Chaigne; Grégoire Cormier; Nathalie Costedoat-Chalumeau; François Lifermann; Alban Deroux; Emilie Berthoux; Emmanuelle Dernis; Thomas Sené; Gilles Blaison; Olivier Lambotte; Benjamin Terrier; Jérémie Sellam; Luc De Saint-Martin; Laurent Chiche; Nicolas Dupin; Luc Mouthon
Journal:  BMC Infect Dis       Date:  2018-07-04       Impact factor: 3.090

8.  Clinical management of an adult with erythema infectiosum: a retrospective case report.

Authors:  David Gryfe; Calvin Wong
Journal:  J Can Chiropr Assoc       Date:  2019-04

Review 9.  Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Authors:  Santa Rasa; Zaiga Nora-Krukle; Nina Henning; Eva Eliassen; Evelina Shikova; Thomas Harrer; Carmen Scheibenbogen; Modra Murovska; Bhupesh K Prusty
Journal:  J Transl Med       Date:  2018-10-01       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.